Eli Lilly Reveals Topline Data From Pivotal Study In Rare Type Of Thyroid Cancer
Portfolio Pulse from Vandana Singh
Eli Lilly has released topline results from the LIBRETTO-531 study evaluating Retevmo as an initial treatment for patients with advanced or metastatic rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC). The study met its primary endpoint, demonstrating a significant improvement in progression-free survival. Full results will be presented at an upcoming medical meeting. Eli Lilly's shares are up 0.91% at $555.19.
August 22, 2023 | 7:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's successful study results could lead to increased investor confidence and a potential rise in stock price.
The successful results from the LIBRETTO-531 study indicate that Eli Lilly's Retevmo could be an effective treatment for RET-mutant medullary thyroid cancer. This could lead to increased sales and revenues for the company, which could in turn boost investor confidence and lead to a rise in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100